Literature DB >> 30215666

Benefits and Pitfalls of Point-of-Care Coagulation Testing for Anticoagulation Management: An ACLPS Critical Review.

Geoffrey D Wool1.   

Abstract

Objectives: Point-of-care (POC) testing is generally less precise and has higher reagent costs per test than laboratory-based assays. However, POC hemostasis testing can offer significant advantages in particular situations: patient-managed warfarin therapy as well as rapid turnaround time heparin management for intraoperative patients. Of note, POC hemostasis testing is generally approved for the purposes of anticoagulation monitoring and is inferior to laboratory coagulation testing for the diagnosis of congenital or acquired coagulopathy.
Methods: The frequently used POC coagulation instruments for POC international normalized ratio and activated clotting time are reviewed, as well as their typical performance relative to central laboratory testing (where available).
Results: Several cases are discussed that highlight the benefits, as well as pitfalls, of POC coagulation testing. Conclusions: POC coagulation testing for anticoagulation monitoring offers advantages in particular situations. Clear policies and protocols must be developed to guide proper use of POC versus central laboratory hemostasis testing.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30215666     DOI: 10.1093/ajcp/aqy087

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  8 in total

Review 1.  Anticoagulation Monitoring for Perioperative Physicians.

Authors:  Cheryl L Maier; Roman M Sniecinski
Journal:  Anesthesiology       Date:  2021-10-01       Impact factor: 8.986

Review 2.  Point of care whole blood microfluidics for detecting and managing thrombotic and bleeding risks.

Authors:  Scott L Diamond; Jason M Rossi
Journal:  Lab Chip       Date:  2021-09-28       Impact factor: 7.517

3.  Has the introduction of direct oral anticoagulants (DOACs) in England increased emergency admissions for bleeding conditions? A longitudinal ecological study.

Authors:  Ana Alfirevic; Jennifer Downing; Konstantinos Daras; Terence Comerford; Munir Pirmohamed; Ben Barr
Journal:  BMJ Open       Date:  2020-05-30       Impact factor: 2.692

4.  Performance of the LumiraDx Platform INR Test in an Anticoagulation Clinic Point-of-Care Setting Compared With an Established Laboratory Reference Method.

Authors:  Robert Campbell Tait; Annielle Hung; Roy S Gardner
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

Review 5.  Management of Coagulopathy in Bleeding Patients.

Authors:  Stefan Hofer; Christoph J Schlimp; Sebastian Casu; Elisavet Grouzi
Journal:  J Clin Med       Date:  2021-12-21       Impact factor: 4.241

6.  Micro-mechanical blood clot testing using smartphones.

Authors:  Justin Chan; Kelly Michaelsen; Joanne K Estergreen; Daniel E Sabath; Shyamnath Gollakota
Journal:  Nat Commun       Date:  2022-02-11       Impact factor: 14.919

7.  Role of POC INR in the early stage of diagnosis of coagulopathy.

Authors:  Florian J Raimann; Marie-Louise Lindner; Christoph Martin; Lukas Jennewein; Thomas Lustenberger; Florian Piekarski; Kai Zacharowski; Christian F Weber
Journal:  Pract Lab Med       Date:  2021-05-23

Review 8.  Updates in Anticoagulation Therapy Monitoring.

Authors:  Hannah L McRae; Leah Militello; Majed A Refaai
Journal:  Biomedicines       Date:  2021-03-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.